- Report
- January 2024
- 200 Pages
Global
From €3982EUR$4,150USD£3,430GBP
- Report
- February 2021
- 360 Pages
United States
From €2303EUR$2,400USD£1,983GBP
- Report
- February 2019
- 105 Pages
Global
From €1238EUR$1,290USD£1,066GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21109EUR$22,000USD£18,181GBP
- Report
- February 2021
- 254 Pages
Global
From €10550EUR$10,995USD£9,086GBP
- Report
- April 2021
- 64 Pages
Global
€21109EUR$22,000USD£18,181GBP
- Report
- January 2019
- 717 Pages
Global
From €21109EUR$22,000USD£18,181GBP
- Report
- June 2019
- 15 Pages
Japan
€9595EUR$10,000USD£8,264GBP
- Report
- June 2019
- 16 Pages
Global
€9595EUR$10,000USD£8,264GBP
- Report
- November 2023
- 35 Pages
Global
From €3541EUR$3,690USD£3,049GBP
Stribild is a combination antiretroviral medication used to treat HIV/AIDS. It is a single-tablet regimen containing four drugs: elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate. Stribild is used to treat HIV-1 infection in adults who have not taken antiretroviral medications before. It works by blocking the action of the virus in the body, preventing it from multiplying and reducing the amount of virus in the body.
Stribild is part of a growing market of HIV/AIDS drugs, which includes other single-tablet regimens and combination therapies. These drugs are designed to help people living with HIV/AIDS manage their condition and reduce the risk of transmitting the virus to others.
Companies in the Stribild market include Gilead Sciences, Inc., ViiV Healthcare, and Mylan N.V. Show Less Read more
